A series of cardiometabolic-related news items has been observed from Dexcom, PharmaSens, Fractyl Health, Daewoong Pharmaceutical, and Madrigal. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: MiniMed hosted its CY Q1 ‘26 (FY Q4 ’26) earnings call (view press release; view slides); Insulet rolled out an updated O5 algorithm and expanded integration with Libre 3 Plus CGM (view press release); and CamDiab’s myLoop AID + Dexcom G7 CGM integration launched in the EU (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly/Camurus, Merck, AstraZeneca, MiniMed, and Ilant Health. Below, FENIX provides highlights and insights for the respective news items.
In the eleventh installment of FENIX’s Obesity Spotlight Series, FENIX has conducted an updated deep dive analysis of Pfizer’s current position in the obesity market. Compared to the previous analysis, which was conducted following the April 2025 termination of danuglipron (previous FENIX insight), this updated Spotlight explores key post‑Metsera acquisition questions, including whether the ~$10B price tag was justified, how Pfizer’s oral AOM strategy is positioned, and whether the company can bring its obesity offering to market sooner than anticipated.
A series of cardiometabolic-related news items has been observed from Hanmi/Lilly, MannKind, Signos, Oura Ring, and Apple. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Dexcom, Lilly/CVS Caremark, Tidepool, Samsung, and the French Ministry of Health. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Abbott, Kailera Therapeutics, MiniMed, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.
A series of cardiometabolic-related news items has been observed from Lilly, Ionis, FDA, and Lannett. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from EMA, Lilly, Beta Bionics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.